House
Sign inCreate account
Drug lookup
Drug reference

copanlisib

PI3Kα and PI3Kδ isoform inhibitor · Antineoplastic agent

PI3Kα and PI3Kδ isoform inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
  • AdalimumabSevereDatabaseDDInter
  • ApalutamideSevereDatabaseDDInter
  • AtazanavirSevereDatabaseDDInter
  • BaricitinibSevereDatabaseDDInter

Mechanism

Copanlisib is an inhibitor of PI3Kα and PI3Kδ isoforms that are expressed in malignant B cells. The efficacy of copanlisib has been linked to inhibition of nuclear factor-κB (NF-κB) signaling and reduced release of interleukin (IL)-6 and IL-10.

Indications

relapsed FL who have received at least two prior systemic therapies

Pharmacokinetics

Half-life
39.1 h (elimination)
Metabolism
CYP3A (substrate)

Side effects

Common
hyperglycemiahypertensiondecreased general strength and energy
Serious
  • pneumonitis
  • diarrhea

Pregnancy & lactation

Pregnancy

D

Drug interactions

Adalimumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Baricitinib
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Boceprevir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Carbamazepine
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Ceritinib
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Certolizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cladribine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Clarithromycin
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Clozapine
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Cobicistat
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Systemic lupus erythematosus
EULAR · Rheumatology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Sjögren's syndrome
EULAR · Rheumatology · 2025

Ask House about copanlisib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team